Touyun Biotech Group Limited (01332) reported no changes in its authorized share capital for 30 November 2025, with the total remaining at HKD500 million, comprising 12.5 billion ordinary shares at a par value of HKD0.04 each.

The total number of issued shares remained unchanged at 2,805,952,149. No movement in treasury shares was recorded.

Under the share option schemes, 278.5 million options were initially outstanding under a scheme adopted on 2 June 2022, with 180.8 million options lapsed, leaving 97.7 million options outstanding. Other schemes showed no material changes in their respective outstanding share options.